Back to top
more

MannKind (MNKD)

(Delayed Data from NSDQ)

$5.82 USD

5.82
2,248,262

-0.07 (-1.19%)

Updated Jul 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates

by Zacks Equity Research

United Therapeutics' (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Tyvaso drive the top line in the quarter.

    MannKind (MNKD) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    MannKind (MNKD) delivered earnings and revenue surprises of -22.22% and 15.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -10% and 34.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    Mednax (MD) Q2 Earnings Match Estimates

    by Zacks Equity Research

    Mednax (MD) delivered earnings and revenue surprises of 0% and 1.34%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

    United Therapeutics (UTHR) Q2 Earnings Miss Estimates, Revenues Up

    by Zacks Equity Research

    United Therapeutics' (UTHR) second-quarter earnings missed estimates, while sales beat the same. Higher sales of Orenitram and Tyvaso drove the top line in the quarter.

    What's in Store for United Therapeutics' (UTHR) Q2 Earnings?

    by Zacks Equity Research

    United Therapeutics' (UTHR) investor focus is likely to have been on sales figures of Tyvaso, Remodulin and Orenitram in the second quarter, as these constitute a vast majority of the total revenues.

    Allogene Therapeutics (ALLO) Moves 16.4% Higher: Will This Strength Last?

    by Zacks Equity Research

    Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

    United Therapeutics (UTHR) Gains on Tyvaso DPI Approval

    by Zacks Equity Research

    The FDA approves United Therapeutics' (UTHR) drug-device combination therapy, Tyvaso DPI, for PAH patients. It is a dry-powder inhalation formulation of Treprostinil. Stock gains 8.8%.

    MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    MannKind (MNKD) delivered earnings and revenue surprises of 0% and 14.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Regenxbio (RGNX) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Regenxbio (RGNX) delivered earnings and revenue surprises of -25.58% and 21.01%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Solid Biosciences Inc. (SLDB) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -22.22% and 46.08%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    United Therapeutics (UTHR) Q4 Earnings & Sales Miss, Stock Down

    by Zacks Equity Research

    United Therapeutics (UTHR) fourth-quarter earnings and sales miss estimates. Higher sales of Tyvaso and Unituxin mainly drive the top line in the quarter, offset by lower sales of other drugs.

    MannKind (MNKD) Reports Q3 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    MannKind (MNKD) delivered earnings and revenue surprises of 20.00% and 8.16%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

    United Therapeutics (UTHR) Q3 Earnings & Sales Beat, Stock Up

    by Zacks Equity Research

    United Therapeutics (UTHR) third-quarter earnings and sales beat estimates. Higher sales of Orenitram and Tyvaso mainly drive the top line in the quarter.

    Will MannKind (MNKD) Report Negative Q3 Earnings? What You Should Know

    by Zacks Equity Research

    MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA (Revised)

    by Zacks Equity Research

    United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.

    United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA

    by Zacks Equity Research

    United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.

    Do Options Traders Know Something About MannKind (MNKD) Stock We Don't?

    by Zacks Equity Research

    Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.

    MannKind (MNKD) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    MannKind (MNKD) delivered earnings and revenue surprises of -25.00% and 31.12%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    United Therapeutics (UTHR) Q2 Earnings & Sales Beat, Stock Up

    by Zacks Equity Research

    United Therapeutics (UTHR) second-quarter earnings and sales beat estimates. Higher sales of Orenitram, Unituxin and Tyvaso mainly drive the top line in the quarter.

    MannKind (MNKD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

    by Zacks Equity Research

    MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Company News for Jun 29, 2021

    by Zacks Equity Research

    Companies in the news are: NTLA, AVXL, MNKD, KYMR

    United Therapeutics (UTHR) Tyvaso DPI Gets FDA's Priority Tag

    by Zacks Equity Research

    United Therapeutics' (UTHR) Tyvaso DPI is a drug device combination therapy, comprising the dry powder formulation of Tyvaso and a small, portable, dry powder inhaler.

    Earnings Preview: MannKind (MNKD) Q1 Earnings Expected to Decline

    by Zacks Equity Research

    MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    MannKind (MNKD) Looks Good: Stock Adds 5.6% in Session

    by Zacks Equity Research

    MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.